{"id":448839,"date":"2024-01-03T14:14:31","date_gmt":"2024-01-03T19:14:31","guid":{"rendered":"https:\/\/platohealth.ai\/nalu-medical-announces-65-million-equity-financing-to-advance-treatment-for-chronic-neuropathic-pain-medical-device-news-magazine\/"},"modified":"2024-01-04T03:54:48","modified_gmt":"2024-01-04T08:54:48","slug":"nalu-medical-announces-65-million-equity-financing-to-advance-treatment-for-chronic-neuropathic-pain-medical-device-news-magazine","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/nalu-medical-announces-65-million-equity-financing-to-advance-treatment-for-chronic-neuropathic-pain-medical-device-news-magazine\/","title":{"rendered":"Nalu Medical Announces $65 Million Equity Financing To Advance Treatment For Chronic Neuropathic Pain – Medical Device News Magazine","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n
\n

Nalu Medical Inc.<\/h2>\n

Nalu Medical<\/a> (Nalu), a private company focused on innovative, minimally invasive, and non-opioid solutions for chronic neuropathic pain, announced today the closing of a $65 million equity financing. The round was led by a new investor, Novo Holdings (Novo). Also participating in the round were all of the Nalu existing significant investors: Gilde Healthcare, MVM Partners, Endeavor Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, and Aperture Venture Partners. The proceeds from this financing will be used to accelerate commercial growth, expand clinical and health-economic evidence, continue product development, and scale operations.<\/p>\n

Expanding Treatment Options<\/h2>\n

\u201cThe Nalu Team is excited about meaningfully expanding and improving the treatment options in the peripheral nerve pain space by setting a new standard of care while also offering a disruptive, minimally invasive, solution in the established spinal cord stimulation market,\u201d said Tom West, President, and CEO of Nalu. \u201cWe continue to invest in building clinical data to expand access for patients who often don\u2019t have other therapeutic options. We are proud that our efforts serve the greater well-being of patients who suffer from chronic pain and benefit those that care for them.\u201d<\/p>\n

\u201cThe differentiated Nalu neurostimulation product has the potential to benefit millions of patients suffering from chronic neuropathic pain,\u201d said Eric Snyder, partner in the Venture Investments team at Novo Holdings. \u201cWe are impressed with their growing body of clinical evidence demonstrating meaningful clinical results in both the emerging market for peripheral nerve stimulation (PNS) and in the established market of spinal cord stimulation (SCS). We are delighted to support the strong management team at Nalu in this period of rapid commercial growth.\u201d<\/p>\n

Geoff Pardo of Gilde Healthcare and Chairman of the Nalu Board Remarks<\/h2>\n

\u201cNalu Medical has made tremendous strides commercially and clinically in the past two years. Novo\u2019s investment in Nalu reflects that progress and the confidence they share in the strong commercial potential for Nalu,\u201d observed Geoff Pardo of Gilde Healthcare and Chairman of the Nalu Board.<\/p>\n<\/div>\n